What is Abcore?
Abcore operates at the intersection of synthetic biology and therapeutic discovery. The company provides a comprehensive platform for the generation of nanobodies and single-domain (VHH) antibodies, which are increasingly vital for next-generation diagnostic and therapeutic applications. Through its end-to-end discovery and development capabilities, Abcore enables clients to accelerate the transition from target identification to custom antibody production. Their proprietary technology stack allows for the rapid screening and optimization of high-affinity binders, positioning the firm as a cornerstone in the evolving landscape of precision medicine and molecular research.
How much funding has Abcore raised?
Abcore has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Abcore
PPP
Public-Private Partnership
What's next for Abcore?
With this late-stage financing, Abcore is well-positioned to scale its operational infrastructure and expand its proprietary phage display library capabilities. The strategic allocation of this capital will likely focus on enhancing throughput for custom antibody production and deepening the firm's research into novel therapeutic targets. As the demand for specialized biologics continues to rise, Abcore's ability to provide scalable, high-quality antibody services will be instrumental in maintaining its competitive advantage. Future growth trajectories suggest a continued emphasis on strategic partnerships and the potential for further technological integration within the broader life sciences ecosystem.
See full Abcore company page
